Prosecution Insights
Last updated: October 04, 2026

Randox Teoranta

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Analysis

Randox Teoranta currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is being handled by 1 distinct examiner, SAOUD, CHRISTINE J. The concentration of work is absolute, as 1 distinct art unit contains the entirety of the portfolio's active prosecution. SAOUD, CHRISTINE J is identified as the busiest examiner for the company, also accounting for 1 busiest examiner pending action.

This indicates a highly focused prosecution stage where all current activity is channeled through a single point of contact at the patent office. Practitioners can expect a streamlined communication path given the lack of diversity in assigned personnel. The alignment of the busiest examiner with the only pending action suggests that the company's immediate patent strategy is entirely dependent on the outcomes from this specific individual. Furthermore, the presence of 1 distinct art unit implies that the technical subject matter is tightly defined within the Biotechnology & Pharmaceuticals sector. This singular art unit assignment simplifies the consistency of legal arguments across the portfolio.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SAOUD, CHRISTINE J 1 58.0% +37.2%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18283652 METHOD OF DETERMINING PROGNOSIS OF CHRONIC KIDNEY DISEASE SAOUD, CHRISTINE J —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18283652 METHOD OF DETERMINING PROGNOSIS OF CHRONIC KIDNEY DISEASE SAOUD, CHRISTINE J —

Top Art Units

Art UnitApps
1645 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18283652 METHOD OF DETERMINING PROGNOSIS OF CHRONIC KIDNEY DISEASE SAOUD, CHRISTINE J 1645 §101§102§112 Non-Final OA — Pending Sep 22, 2023

Managing Randox Teoranta's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month